Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson for BBB Disruption in Glioma
NCT02389738Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of regadenoson in high-grade glioma (HGG), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Area Under the Curve of Temozolomide Concentration in Brain Interstitium at 18 hours. Started Feb 2015; status: completed.
02
Drugs
regadenoson
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02389738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389738.